Menin-MLL inhibitor 3 MedChemExpress (MCE)

Product Name	MI-3
Synonyms	MI3 MI-3 MI 3 4-[4-(4 THIENO[2 5-dihydro-5 5-DIHYDRO-5 Synonyms MI3 MI-3 MI 3 4-[4-(4 THIENO[2 5-dihydro-5 5-DIHYDRO-5 3-D]PYRIMIDINE Menin-MLL inhibitor 3 MENIN-MLL INHIBITOR 3 MI-3 (Menin-MLL Inhibitor) MI-3(MENIN-MLL INHIBITOR 3) 5-DIMETHYL-2-THIAZOLYL)-1-PIPERAZINYL]-6-(1-METHYLETHYL) 5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl) 4-[4-(4,5-Dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl)thieno[2,3-d]pyrimidine Thieno[2,3-d]pyriMidine, 4-[4-(4,5-dihydro-5,5-diMethyl-2-thiazolyl)-1-piperazinyl]-6-(1-Methylethyl)-
CAS	1271738-59-0
EINECS
Chemical Formula	C18H25N5S2
Molecular Weight	375.55
inchi
Package	10 mM * 1 mL;5 mg;10 mg;25 mg;50 mg
Price	Get quote
Descriptions	MI-3 MI-3 MedChemExpress (MCE) HY-15223 1271738-59-0 Menin-MLL inhibitor 3 99.58% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions MI-3 MI-3 MedChemExpress (MCE) HY-15223 1271738-59-0 Menin-MLL inhibitor 3 99.58% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM. MI-3 (12.5-50 μM HEK293 cells) treatment effectively inhibits the menin-MLL-AF9 interaction in human cells[1]. MI-3 (0-1.6 μM 72 hours KOPN-8 and MV4 11 cells) treatment shows an effective and dose-dependent growth inhibition in KOPN-8, MV4 and ME-1 cells[1]. MI-3 (12.5-50 μM 48 hours MV4 11 cells) treatment results in a substantial, and dose-dependent increase in Annexin V and AnnexinV/propidium iodide (PI) cells, demonstrating an increase in the number of cells undergoing apoptosis[1]. MI-3 (6.25-25 μM 6 days THP-1 cells) treatment results in substantially reduced expression of HOXA9 and MEIS1[1]. IC50: 648 nM (menin-MLL) Kd: 201 nM (menin-MLL)[1] In Vitro MI-3 (12.5-50 μM HEK293 cells) treatment effectively inhibits the menin-MLL-AF9 interaction in human cells[1]. MI-3 (0-1.6 μM 72 hours KOPN-8 and MV4 11 cells) treatment shows an effective and dose-dependent growth inhibition in KOPN-8, MV4 and ME-1 cells[1]. MI-3 (12.5-50 μM 48 hours MV4 11 cells) treatment results in a substantial, and dose-dependent increase in Annexin V and AnnexinV/propidium iodide (PI) cells, demonstrating an increase in the number of cells undergoing apoptosis[1]. MI-3 (6.25-25 μM 6 days THP-1 cells) treatment results in substantially reduced expression of HOXA9 and MEIS1[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MI-3 Related Antibodies Western Blot Analysis[1] Cell Line: HEK293 cells \| \| \| \| \| \| \| \| \| \| [1]. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology (2012), 8(3), 277-284. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact